Key facts
- Seqens’s last known valuation is $1.6B (Nov 2022).
- It has raised $543.8M; the latest was PE Growth/Expansion ($570K) in Mar 2025.
- Notable investors include Bpifrance, Societe Generale Capital Partenaires, Caisse des Depots Group, Crescent Capital Group, Eximium — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Seqens
- ·The full record, as it builds
Funding rounds
No funding rounds for Seqens are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Seqens
Manufacturer of pharmaceutical ingredients and specialty ingredients based in Ecully, France. The company specializes in aspirin, paracetamol, salicylic acid, para-aminophenol, soda ash, sodium bicarbonate, phenol, oxygenated solvents, ferric chloride and other active pharma ingredients, primarily serving demanding industries such as healthcare, electronics, cosmetics, food and household cleaners.
- Sector
- Healthcare
- HQ
- Ecully, France
- Founded
- 2003
- Employees
- 2,700
- Website
- seqens.com/
- Ownership
- Privately Held (backing)
Seqens doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Seqens shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Seqens in its N-PORT filings yet. We sweep new filings monthly.